[Hyperkalemia - current therapuetic strategies]

Area of Science:

• Nephrology
• Internal Medicine
• Pharmacology

Background:

• Hyperkalemia is a critical medical condition necessitating urgent treatment and long-term management strategies.
• Patients with chronic kidney disease (CKD) are particularly susceptible to hyperkalemia due to impaired kidney function and common comorbidities like diabetes and heart failure.
• Medications, especially renin-angiotensin-aldosterone system inhibitors (RAASi), frequently contribute to hyperkalemia in these patients.

Purpose of the Study:

• To highlight the challenges in managing hyperkalemia, particularly in patients with CKD.
• To discuss the limitations of current therapeutic approaches for restoring potassium homeostasis.
• To introduce the potential of novel medications in shifting hyperkalemia management towards preventive strategies.

Main Methods:

• Review of current medical literature on hyperkalemia management.
• Analysis of the role of comorbidities and medications in hyperkalemia development.
• Evaluation of the therapeutic potential of new agents like patiromer and ZS-9.

Main Results:

• Current management often focuses on treating triggers rather than providing continuous potassium regulation.
• New medications, patiromer and ZS-9, show promise in stabilizing serum potassium levels.
• These new agents may enable the continued use of essential RAASi therapy by mitigating hyperkalemia risk.

Conclusions:

• Effective management of hyperkalemia requires both immediate intervention and strategies to prevent recurrence.
• Novel potassium binders represent a significant advancement, potentially transforming hyperkalemia treatment from reactive to proactive.
• Preventive measures using new medications can improve patient outcomes by allowing the use of life-sustaining therapies that might otherwise induce hyperkalemia.